The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patterns of failure in metastatic non-small cell lung cancer (mNSCLC) treated with first line pembrolizumab and use of local therapy in patients with oligoprogression.
 
Cole Friedes
No Relationships to Disclose
 
Nikhil Yegya-Raman
No Relationships to Disclose
 
Siqi Zhang
No Relationships to Disclose
 
Michelle Iocolano
No Relationships to Disclose
 
Roger B. Cohen
Honoraria - AstraZeneca
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Cantargia AB; Coherus Biosciences; Fstar Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); F-Star Biotechnology (Inst); Innate Pharma (Inst); Macrogenics (Inst); Xencor (Inst)
 
Charu Aggarwal
Consulting or Advisory Role - AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim; Celgene; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech; Janssen; Lilly; Merck; Pfizer; Sanofi/Regeneron; Shionogi; Turning Point Therapeutics
Speakers' Bureau - AstraZeneca (I); Roche/Genentech (I)
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Incyte (Inst); Macrogenics (Inst); Merck Sharp & Dohme (Inst)
 
Jeffrey C. Thompson
Consulting or Advisory Role - AstraZeneca
Research Funding - Delfi Diagnostics (Inst); Incyte (Inst)
 
Melina Elpi Marmarelis
Stock and Other Ownership Interests - Bluebird Bio; Gilead Sciences; Johnson & Johnson; Merck; Pfizer; Portola Pharmaceuticals
Honoraria - AstraZeneca; Blueprint Medicines; Blueprint Medicines; Health Advances (I); Janssen Oncology; Novocure; Takeda; Targeted Oncology; Thermo Fisher Scientific
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Ikena Oncology
Research Funding - AstraZeneca (Inst); Lilly (Inst); Trizell (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Novocure
 
William C. Levin
No Relationships to Disclose
 
Keith A. Cengel
Stock and Other Ownership Interests - Symphotek; Symphotek
Consulting or Advisory Role - Novocure
Patents, Royalties, Other Intellectual Property - US20190099491A1 Sensitizing Cells to Proton Radiation; US9999779B2 Cell, tissue and organ protection using a magnetic field
Travel, Accommodations, Expenses - Novocure
 
Christine Agnes Ciunci
Honoraria - Imedex/HMP
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); MacroGenics (Inst); Merck (Inst)
 
Aditi Puri Singh
Consulting or Advisory Role - Precision HEOR (I)
 
Christopher Davella
No Relationships to Disclose
 
Christiana Davis
No Relationships to Disclose
 
Corey J. Langer
Honoraria - AstraZeneca; Genentech/Roche; Lilly/ImClone; Merck; Takeda Science Foundation
Consulting or Advisory Role - Abbott Biotherapeutics; ARIAD; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Gilead Sciences; Lilly/ImClone; Merck; Novocure; Pfizer; Regeneron; Takeda
Research Funding - Advantagene (Inst); Amgen; Ariad (Inst); AstraZeneca; Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte; Inovio Pharmaceuticals (Inst); Johnson & Johnson/Janssen; Lilly; Merck (Inst); Stem CentRx (Inst); Trizell (Inst)
Other Relationship - Amgen; Lilly; OncoCyte; Peregrine Pharmaceuticals; Synta
 
Steven J Feigenberg
No Relationships to Disclose